| Where Approvals Are Lost | CMC deficiencies are consistently among the most cited causes of first-cycle approval failures for ATMPs — not clinical data gaps, not safety signals. |
| The Core Principle | In advanced therapies, the manufacturing process is the product. Change the process and you may have changed the therapy. |
| The Organizational Gap | Regulatory Affairs, Manufacturing, and Quality share CMC accountability but none owns the strategic integration. Decisions get made by default, not by design. |
| The Four Shifts That Protect Timelines | CMC strategy at program initiation, commercial-scale thinking in clinical design, data authored with regulatory intent, and post-approval lifecycle pre-planned. |
| The Competitive Divide | The programs that hold their timelines are not distinguished by better science. They are distinguished by when and how CMC strategy entered the development conversation. |
| The AVS Approach | How AVS builds integrated CMC strategy into ATMP programs from initiation through post-approval lifecycle management. |
The organizations that hold their ATMP timelines are not distinguished by better science. They are distinguished by when and how CMC strategy entered the development conversation.
You have the clinical data. You have the breakthrough designation. You may even have patient advocacy behind you.
And your program is still behind schedule.
If that describes your reality, stop looking at your clinical team. The delay is almost certainly sitting inside your CMC strategy — or more precisely, the absence of one designed to survive regulatory scrutiny at scale.
This is the conversation most executive teams have too late. This article is your opportunity to have it now.
CMC strategy is the integrated planning of chemistry, manufacturing, and controls activities across the full product lifecycle — and in ATMPs, it is the foundation on which regulatory approval is built or lost.
In small-molecule development, CMC was a downstream operational function. In ATMPs — cell therapies, gene therapies, and tissue-engineered products — that assumption is program-ending. Cell therapies involve living donor-derived materials with inherent biological variability. Gene therapies require viral vector manufacturing at commercial scale, with a level of consistency and yield that traditional biologics experience often does not prepare organizations for. Tissue-engineered products add further complexity by falling between device and biologic regulatory frameworks, creating CMC requirements that standard development models fail to address.
What these products have in common is that the manufacturing process is the product. Change the process, and you may change the therapy itself. Regulators understand this reality — the question is whether your organization does as well.
Every process change introduces a comparability challenge. Too often, organizations don't recognize the impact until delays, additional studies, and missed milestones become unavoidable.
CMC deficiencies are consistently among the most cited causes of first-cycle approval failures for ATMPs — not clinical data gaps, not safety signals. The pattern is well-documented in FDA Complete Response Letters and in the experience of organizations that have navigated it, and those that have not.
Each comparability gap that surfaces late triggers additional studies, agency review cycles, and re-submission timelines that compress the commercial window in ways that are rarely fully recoverable. The organizations issuing statements about "unexpected regulatory delays" are not dealing with unexpected science. They are dealing with predictable CMC failures embedded in their programs long before the BLA was filed.
The programs that hold their timelines are not distinguished by better science. They are distinguished by when and how CMC strategy entered the development conversation.
In most organizations, responsibility for CMC is divided across three critical functions — yet strategic integration often falls through the cracks.
Owns the filing strategy — but rarely has full visibility into the manufacturing decisions that will define what can be filed and when.
Owns the process, scale-up, and supporting data package — but decisions are often finalized without accounting for their regulatory and comparability implications.
Owns GMP compliance and quality systems — but operates in parallel with filing strategy rather than in integrated alignment with it.
Because these functions operate in parallel rather than in tandem, strategic decisions are made by default rather than by design. Regulatory commitments are made without manufacturing visibility. Scale-up decisions are finalized without accounting for comparability implications. Data systems generate operational outputs that fail to map to what regulators actually need to see in a submission package.
The problem is not team performance — it is organizational architecture. Hidden at the functional level, it becomes visible only when viewed across the enterprise. And only executive leadership has the authority to close the gap.
Regulatory Affairs learns of a manufacturing change after it has been finalized. Quality is brought in to document a decision that has already been made. The comparability study is designed reactively — to answer a gap that should have been anticipated — rather than proactively as part of a pre-planned strategy. The result is a submission that arrives at the agency with questions already built into the data package.
There are four strategic decisions that define ATMP program timelines — all of which must be made earlier than most organizations make them.
Process decisions made in Phase 1 define the regulatory flexibility available for the entire lifecycle. Organizations that treat CMC strategy as a Phase 2 or Phase 3 activity are carrying a timeline liability that compounds with every subsequent development decision. The cost of building CMC strategy late is not the cost of the strategy — it is the cost of every development decision that was made without it.
Clinical processes built without commercial scale in mind produce comparability gaps that surface at the worst moment: late Phase 3, against an already-committed launch timeline. The question is not only whether your current process works — it is whether it is recognizably continuous with the one you will need at commercial scale. The distance between those two points is where approval delays are born.
Data quality is necessary but not sufficient. Regulators ask not whether you have data, but whether your data anticipates and answers their questions. A package that does not tell a coherent story — regardless of the underlying quality — generates queries and review cycles that erode timelines. The most successful submissions anticipate concerns and address them before they are raised. The distinction between a data package and a regulatory narrative is where review cycles are won or lost.
Process changes and facility transfers are not operational events. They are regulatory events, each carrying notification obligations and comparability requirements. Organizations that treat them as surprises pay in additional data packages and eroded agency relationships. A pre-planned post-approval CMC strategy converts predictable events into managed ones — and preserves the institutional knowledge of why pre-approval decisions were made in the first place.
If the answers to these questions are uncertain, the risk is already inside your program.
If any of these questions reveal uncertainty today, that same uncertainty is likely to resurface during regulatory review — at a significantly higher cost in time, resources, and risk.
For organizations building their first ATMP program, we provide the strategic infrastructure to avoid the CMC failures that derail programs at the worst possible moment. For established developers managing late-stage transitions or post-approval complexity, we deliver the gap assessment and remediation architecture to make those transitions defensible.
CMC strategy is the integrated planning of Chemistry, Manufacturing, and Controls activities across the full product lifecycle, from first-in-human studies through post-approval. In ATMPs, it is not a downstream function. It is the foundation on which regulatory approval is built or lost.
Because the manufacturing process is the product. Unlike small molecules, where the drug substance can be characterized independently of how it was made, ATMPs are defined by their manufacturing process. Process changes create comparability obligations that small-molecule frameworks were not designed to manage.
At program initiation. Process decisions made in Phase 1 define the regulatory flexibility available for the entire lifecycle. Organizations that treat CMC strategy as a late-stage activity are carrying timeline risk that compounds with every subsequent development decision.
AVS Life Sciences builds CMC strategy into ATMP programs from initiation — not as a late-stage remediation exercise, but as a foundational component of the development architecture.
Comparability gaps. When process changes — such as scale-up, site transfers, and manufacturing optimization — are not managed within a pre-planned comparability strategy, regulators require additional data that was not anticipated in the development plan. These gaps are predictable and largely avoidable.
A comparability strategy is a pre-planned framework for demonstrating that process changes do not adversely affect the safety, identity, purity, or potency of the therapy. Without one, every process change becomes a reactive regulatory event. With one, changes are managed within a defined structure that regulators can evaluate predictably.
AVS Life Sciences designs comparability strategies as part of integrated CMC planning — converting predictable regulatory events into managed ones rather than reactive ones.
